Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223433 | 0.85 | AKT1 (0.35) | KMT2AMEN1POLBNPSR1 | |
| SCHEMBL22223477 | 0.81 | KMT2A (0.42) | KMT2A | |
| SCHEMBL22223354 | 0.78 | KMT2A (0.39) | KMT2APLA2G4APOLB | |
| SCHEMBL22223487 | 0.67 | LPAR2 (0.39) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL22223491 | 0.63 | AKT1 (0.37) | NPSR1 | |
| SCHEMBL22223355 | 0.62 | FFAR4 (0.45) | KMT2AMEN1 | |
| SCHEMBL29552983 | 0.61 | NOD1 (0.52) | KMT2A | |
| SCHEMBL26288436 | 0.60 | KMT2A (0.52) | KMT2APLA2G4AMEN1POLB | |
| SCHEMBL23344142 | 0.59 | KMT2A (0.49) | KMT2APOLB | |
| SCHEMBL22690652 | 0.59 | KMT2A (0.36) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | F2 4332/4885PRSS1 2466/4885PRSS2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.